BIOMAT Database Logo BIOMAT Database Logo

The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. 2003

Colette J Smith, and Caroline A Sabin, and Fiona C Lampe, and Sabine Kinloch-de-Loes, and Helen Gumley, and Anne Carroll, and Beth Prinz, and Mike Youle, and Margaret A Johnson, and Andrew N Phillips
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, UK. c.smith@pcps.ucl.ac.uk

OBJECTIVE To study the long-term CD4 cell responses to highly active antiretroviral therapy (HAART) in treatment-naive patients whose viral loads remained below 500 copies/ml for prolonged periods. METHODS A total of 237 patients whose viral loads remained below 500 copies/ml for one year or more. Median follow-up was 1.9 years. METHODS CD4 cell counts were analysed to investigate long-term immunological response using mixed-effects models with the slope allowed to change after 1, 12 and 24 months of HAART. RESULTS The median baseline CD4 cell count was 175 cells/mm3. After an initial rapid increase in the first month after HAART (97.2 cells/mm3 a month), increases in CD4 cell counts continued less rapidly (11.6 cells/mm3 a month). This increase slowed by 2.4 cells/mm3 a month after one year. CD4 cell counts continued increasing after 2 years, but the rate of increase again slowed (estimated slope at 2 years 5.4 cells/mm3 a month; decrease in slope from year 2 compared with years 1-2 3.7 cell/mm3 a month). A total of 198 out of 211 patients (94%) with measurements at baseline and one year experienced an increase in CD4 cell counts in this interval; 81 and 67% had an increasing slope between 1 and 2 and 2 and 3 years, respectively. By the end of follow-up, CD4 cell counts had increased by 319 cells/mm3, and were more than 500 cells/mm3 in 40% of patients. CONCLUSIONS Although the rate of immune recovery slowed after 2 years, CD4 cell counts rose in most and began to return to levels seen in HIV-negative individuals.

UI MeSH Term Description Entries
D008297 Male Males
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014766 Viremia The presence of viruses in the blood. Viremias
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018791 CD4 Lymphocyte Count The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer. Lymphocyte Count, CD4,T4 Lymphocyte Count,CD4 Cell Counts,CD4 Counts,CD4+ Cell Counts,CD4+ Counts,CD4 Cell Count,CD4 Count,CD4 Lymphocyte Counts,CD4+ Cell Count,CD4+ Count,Count, T4 Lymphocyte,Counts, T4 Lymphocyte,Lymphocyte Count, T4,Lymphocyte Counts, CD4,Lymphocyte Counts, T4,T4 Lymphocyte Counts
D019562 Viral Load The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression. Viral Burden,Virus Titer,Burden, Viral,Load, Viral,Titer, Virus

Related Publications

Colette J Smith, and Caroline A Sabin, and Fiona C Lampe, and Sabine Kinloch-de-Loes, and Helen Gumley, and Anne Carroll, and Beth Prinz, and Mike Youle, and Margaret A Johnson, and Andrew N Phillips
Polyactin A increases CD4(+) T-cell counts in HIV-infected individuals with insufficient immunologic response to highly active antiretroviral therapy.
January 2014, International journal of STD & AIDS,
Colette J Smith, and Caroline A Sabin, and Fiona C Lampe, and Sabine Kinloch-de-Loes, and Helen Gumley, and Anne Carroll, and Beth Prinz, and Mike Youle, and Margaret A Johnson, and Andrew N Phillips
Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?
February 2012, The Journal of infectious diseases,
Colette J Smith, and Caroline A Sabin, and Fiona C Lampe, and Sabine Kinloch-de-Loes, and Helen Gumley, and Anne Carroll, and Beth Prinz, and Mike Youle, and Margaret A Johnson, and Andrew N Phillips
CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study.
March 1998, Lancet (London, England),
Colette J Smith, and Caroline A Sabin, and Fiona C Lampe, and Sabine Kinloch-de-Loes, and Helen Gumley, and Anne Carroll, and Beth Prinz, and Mike Youle, and Margaret A Johnson, and Andrew N Phillips
Highly-active antiretroviral therapy and oral opportunistic microorganisms in HIV-positive individuals of Thailand.
May 2016, Journal of investigative and clinical dentistry,
Colette J Smith, and Caroline A Sabin, and Fiona C Lampe, and Sabine Kinloch-de-Loes, and Helen Gumley, and Anne Carroll, and Beth Prinz, and Mike Youle, and Margaret A Johnson, and Andrew N Phillips
[Human papillomavirus (HPV) induced lesions in HIV positive individuals after highly active antiretroviral therapy].
November 2002, Revue de stomatologie et de chirurgie maxillo-faciale,
Colette J Smith, and Caroline A Sabin, and Fiona C Lampe, and Sabine Kinloch-de-Loes, and Helen Gumley, and Anne Carroll, and Beth Prinz, and Mike Youle, and Margaret A Johnson, and Andrew N Phillips
[Human papillomavirus (HPV) induced lesions in HIV-positive individuals after highly active antiretroviral therapy].
April 2002, Annales de dermatologie et de venereologie,
Colette J Smith, and Caroline A Sabin, and Fiona C Lampe, and Sabine Kinloch-de-Loes, and Helen Gumley, and Anne Carroll, and Beth Prinz, and Mike Youle, and Margaret A Johnson, and Andrew N Phillips
CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy.
April 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Colette J Smith, and Caroline A Sabin, and Fiona C Lampe, and Sabine Kinloch-de-Loes, and Helen Gumley, and Anne Carroll, and Beth Prinz, and Mike Youle, and Margaret A Johnson, and Andrew N Phillips
Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy.
November 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Colette J Smith, and Caroline A Sabin, and Fiona C Lampe, and Sabine Kinloch-de-Loes, and Helen Gumley, and Anne Carroll, and Beth Prinz, and Mike Youle, and Margaret A Johnson, and Andrew N Phillips
Micronutrient supplementation increases CD4 count in HIV-infected individuals on highly active antiretroviral therapy: a prospective, double-blinded, placebo-controlled trial.
August 2006, Journal of acquired immune deficiency syndromes (1999),
Colette J Smith, and Caroline A Sabin, and Fiona C Lampe, and Sabine Kinloch-de-Loes, and Helen Gumley, and Anne Carroll, and Beth Prinz, and Mike Youle, and Margaret A Johnson, and Andrew N Phillips
Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana.
February 2011, PloS one,
Copied contents to your clipboard!